Cargando…
Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis
In a previous study, we established a one-step methylation-specific polymerase chain reaction (OS-MSP) assay for the detection of methylated DNA (met-DNA) and total DNA levels in serum. For the present study, this OS-MSP assay was used for patients with breast cancer treated with neoadjuvant chemoth...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063626/ https://www.ncbi.nlm.nih.gov/pubmed/24959284 http://dx.doi.org/10.3892/ol.2014.2068 |
_version_ | 1782321824213762048 |
---|---|
author | FUJITA, NORIKO KAGARA, NAOFUMI YAMAMOTO, NORIAKI SHIMAZU, KENZO SHIMOMURA, ATSUSHI SHIMODA, MASAFUMI MARUYAMA, NAOMI NAOI, YASUTO MORIMOTO, KOJI ODA, NAOFUMI KIM, SEUNG JIN NOGUCHI, SHINZABURO |
author_facet | FUJITA, NORIKO KAGARA, NAOFUMI YAMAMOTO, NORIAKI SHIMAZU, KENZO SHIMOMURA, ATSUSHI SHIMODA, MASAFUMI MARUYAMA, NAOMI NAOI, YASUTO MORIMOTO, KOJI ODA, NAOFUMI KIM, SEUNG JIN NOGUCHI, SHINZABURO |
author_sort | FUJITA, NORIKO |
collection | PubMed |
description | In a previous study, we established a one-step methylation-specific polymerase chain reaction (OS-MSP) assay for the detection of methylated DNA (met-DNA) and total DNA levels in serum. For the present study, this OS-MSP assay was used for patients with breast cancer treated with neoadjuvant chemotherapy (NAC) in order to investigate the prognostic significance of met-DNA and total DNA levels. Following treatment with NAC and prior to surgery, serum samples obtained from 120 patients with stage II/III breast cancer were subjected to the OS-MSP assay for analysis of the glutathione S-transferase pi 1, Ras association (RalGDS/AF-6) domain family member 1 and retinoic acid receptor β2 genes. The detection of methylation in a minimum of one of these genes indicated a positive outcome of the assay. The total DNA content of the serum was also determined. Of the 120 stage II/III patients, seven (6%) were positive for met-DNA in serum and showed a significantly worse overall survival (OS) time compared with patients negative for met-DNA (n=113) (5-year OS, 43 vs. 85%; P=0.002). The patients with high total DNA levels in serum (n=40) also showed a significantly worse OS compared with those with low total DNA levels (n=80) (65 vs. 91%; P<0.001). The presence of met-DNA and high total DNA levels in the serum were found to be significant prognostic factors that are independent of a pathological complete response by multivariate analysis. Following NAC, met-DNA and high total DNA levels in the serum detected with the OS-MSP assay constitute novel prognostic factors for patients with breast cancer; this may be clinically useful for the prognosis prediction for patients who do not achieve a pathological complete response following NAC. |
format | Online Article Text |
id | pubmed-4063626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-40636262014-06-23 Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis FUJITA, NORIKO KAGARA, NAOFUMI YAMAMOTO, NORIAKI SHIMAZU, KENZO SHIMOMURA, ATSUSHI SHIMODA, MASAFUMI MARUYAMA, NAOMI NAOI, YASUTO MORIMOTO, KOJI ODA, NAOFUMI KIM, SEUNG JIN NOGUCHI, SHINZABURO Oncol Lett Articles In a previous study, we established a one-step methylation-specific polymerase chain reaction (OS-MSP) assay for the detection of methylated DNA (met-DNA) and total DNA levels in serum. For the present study, this OS-MSP assay was used for patients with breast cancer treated with neoadjuvant chemotherapy (NAC) in order to investigate the prognostic significance of met-DNA and total DNA levels. Following treatment with NAC and prior to surgery, serum samples obtained from 120 patients with stage II/III breast cancer were subjected to the OS-MSP assay for analysis of the glutathione S-transferase pi 1, Ras association (RalGDS/AF-6) domain family member 1 and retinoic acid receptor β2 genes. The detection of methylation in a minimum of one of these genes indicated a positive outcome of the assay. The total DNA content of the serum was also determined. Of the 120 stage II/III patients, seven (6%) were positive for met-DNA in serum and showed a significantly worse overall survival (OS) time compared with patients negative for met-DNA (n=113) (5-year OS, 43 vs. 85%; P=0.002). The patients with high total DNA levels in serum (n=40) also showed a significantly worse OS compared with those with low total DNA levels (n=80) (65 vs. 91%; P<0.001). The presence of met-DNA and high total DNA levels in the serum were found to be significant prognostic factors that are independent of a pathological complete response by multivariate analysis. Following NAC, met-DNA and high total DNA levels in the serum detected with the OS-MSP assay constitute novel prognostic factors for patients with breast cancer; this may be clinically useful for the prognosis prediction for patients who do not achieve a pathological complete response following NAC. D.A. Spandidos 2014-07 2014-04-15 /pmc/articles/PMC4063626/ /pubmed/24959284 http://dx.doi.org/10.3892/ol.2014.2068 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles FUJITA, NORIKO KAGARA, NAOFUMI YAMAMOTO, NORIAKI SHIMAZU, KENZO SHIMOMURA, ATSUSHI SHIMODA, MASAFUMI MARUYAMA, NAOMI NAOI, YASUTO MORIMOTO, KOJI ODA, NAOFUMI KIM, SEUNG JIN NOGUCHI, SHINZABURO Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title_full | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title_fullStr | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title_full_unstemmed | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title_short | Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
title_sort | methylated dna and high total dna levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4063626/ https://www.ncbi.nlm.nih.gov/pubmed/24959284 http://dx.doi.org/10.3892/ol.2014.2068 |
work_keys_str_mv | AT fujitanoriko methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT kagaranaofumi methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT yamamotonoriaki methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT shimazukenzo methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT shimomuraatsushi methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT shimodamasafumi methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT maruyamanaomi methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT naoiyasuto methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT morimotokoji methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT odanaofumi methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT kimseungjin methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis AT noguchishinzaburo methylateddnaandhightotaldnalevelsintheserumofpatientswithbreastcancerfollowingneoadjuvantchemotherapyarepredictiveofapoorprognosis |